RAPID
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Project Team: Alexandre Theocharides (MOH), Markus G. Manz (MOH), Berend Snijder (ETH)
Funding: CHF 2 Mio. (2024-2026), ETH PHRT
Keywords: Acute Myeloid Leukemia, Pharmacoscopy, Precision Medicine
With an overall survival of below 12 months, the outcome of relapsed/refractory acute myeloid leukemia (rr-AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID trial aims to show that Pharmacoscopy (PCY), an ETH-developed functional precision medicine platform, helps improve therapy selection for patients suffering from rr-AML, for the first time in a randomized and controlled mutlicenter (Zurich, Bern, Basel) clinical trial. In doing so, we aim to validate PCY for precision oncology in AML, improve the lives of rr-AML patients, and further develop the PCY platform, optimized for distributed drug testing in clinical centers in Switzerland.
“While several treatment options for patients with relapsed/refractory acute myeloid leukemia exist, none of them have been compared in a randomized trial, which makes clinical decision making difficult. RAPID is the first prospective, randomized clinical trial to integrate drug screening data into the treatment decision process in order to identify the best possible treatment option for relapsed/refractory acute myeloid leukemia patients.”
Prof. Dr. med. Alexandre Theocharides - Director CCCZ Clinical Trials Program
